公司资料
GeoVax Labs 股价、新闻与催化剂
- 股票代码:
- GOVX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.32 USD (-3.56%)
收盘价
最后更新: 2026年10月1日
10.9M USD
市值
股价为何变动
截至 2026年10月1日，GOVX 下跌 3.56%，收于 $0.3222。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Vaccine and Immunotherapy Company
GeoVax Labs develops vaccines and cancer immunotherapies using modified vaccinia Ankara vectors and gene-directed therapy. Its portfolio targets emerging infectious diseases and difficult-to-treat solid tumors.
GEO-MVA for Mpox and Smallpox
GEO-MVA is a live, non-replicating MVA vaccine being developed for protection against mpox and smallpox. The program is intended to support public-health preparedness and provide an alternative vaccine option for vulnerable populations.
Immunobridging Regulatory Strategy
Because efficacy trials against smallpox are not feasible, GeoVax plans to compare immune responses generated by GEO-MVA with those from an established vaccine. A successful immunobridging study could support regulatory submissions.
Gedeptin Cancer Gene Therapy
Gedeptin is a gene-directed enzyme prodrug therapy delivered into tumors. It is designed to convert an administered prodrug into an active anticancer agent locally and is being explored with checkpoint inhibition.
MVA Platform Capabilities
The company's MVA technology can deliver multiple antigens in a single vaccine and stimulate both antibody and T-cell responses. Government relationships and external manufacturing partners are important to development and stockpile opportunities.
未来催化剂
- Initiation of the pivotal GEO-MVA immunobridging study in the fourth quarter of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。